Comparative Pharmacology
Head-to-head clinical analysis: HETLIOZ versus ROZEREM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETLIOZ versus ROZEREM.
HETLIOZ vs ROZEREM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melatonin receptor agonist; selective agonist at MT1 and MT2 receptors in the suprachiasmatic nucleus, regulating circadian rhythms.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; modulates circadian rhythm and sleep-wake cycle.
20 mg orally once daily at bedtime, take within 30 minutes of bedtime, with or without food.
8 mg orally once daily, 30 minutes before bedtime, not to exceed 8 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.3-1.5 hours. No clinically relevant accumulation with daily dosing.
Ramelteon: 1-2.6 hours. Active metabolite M-II: 2-5 hours. Clinical context: Short half-life supports use for sleep initiation without significant next-day residual effects.
Primarily hepatic metabolism; 77-88% excreted in feces as metabolites, 13-23% in urine as metabolites. <1% excreted unchanged.
Primarily renal (about 84% of total clearance), with approximately 70-80% of an oral dose excreted in urine as glucuronide conjugates of ramelteon and its active metabolite M-II. Fecal excretion accounts for about 4%.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist